0000899243-20-018653.txt : 20200707 0000899243-20-018653.hdr.sgml : 20200707 20200707185730 ACCESSION NUMBER: 0000899243-20-018653 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200702 FILED AS OF DATE: 20200707 DATE AS OF CHANGE: 20200707 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Vifor (International) Ltd CENTRAL INDEX KEY: 0001675217 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35420 FILM NUMBER: 201016922 BUSINESS ADDRESS: STREET 1: RECHENSTRASSE 37 CITY: ST. GALLEN STATE: V8 ZIP: 9000 BUSINESS PHONE: 41 58 851 80 00 MAIL ADDRESS: STREET 1: RECHENSTRASSE 37 CITY: ST. GALLEN STATE: V8 ZIP: 9000 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Vifor Pharma Ltd. CENTRAL INDEX KEY: 0001416422 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35420 FILM NUMBER: 201016923 BUSINESS ADDRESS: STREET 1: UNTERMATTWEG 8 CITY: BERNE STATE: V8 ZIP: CH-3027 BUSINESS PHONE: 41 58 852 81 11 MAIL ADDRESS: STREET 1: UNTERMATTWEG 8 CITY: BERNE STATE: V8 ZIP: CH-3027 FORMER NAME: FORMER CONFORMED NAME: Galenica AG DATE OF NAME CHANGE: 20071026 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Vifor Fresenius Medical Care Renal Pharma Ltd. CENTRAL INDEX KEY: 0001757924 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35420 FILM NUMBER: 201016924 BUSINESS ADDRESS: STREET 1: RECHENSTRASSE 37 STREET 2: CH-9014 CITY: ST. GALLEN STATE: V8 ZIP: 9014 BUSINESS PHONE: 0041588518051 MAIL ADDRESS: STREET 1: RECHENSTRASSE 37 STREET 2: CH-9014 CITY: ST. GALLEN STATE: V8 ZIP: 9014 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ChemoCentryx, Inc. CENTRAL INDEX KEY: 0001340652 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943254365 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 850 MAUDE AVENUE CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 BUSINESS PHONE: 650-210-2900 MAIL ADDRESS: STREET 1: 850 MAUDE AVENUE CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-07-02 0 0001340652 ChemoCentryx, Inc. CCXI 0001675217 Vifor (International) Ltd RECHENSTRASSE 37 CH-9014 ST. GALLEN V8 SWITZERLAND 0 0 1 0 0001416422 Vifor Pharma Ltd. RECHENSTRASSE 37 CH-9014 ST. GALLEN V8 SWITZERLAND 0 0 1 0 0001757924 Vifor Fresenius Medical Care Renal Pharma Ltd. RECHENSTRASSE 37 CH-9014 ST. GALLEN V8 SWITZERLAND 0 0 1 0 Common Stock, par value $0.001 per share 2020-07-02 4 S 0 15376 56.4739 D 10661449 I See Footnotes Common Stock, par value $0.001 per share 2020-07-02 4 S 0 36417 57.3816 D 10625032 I See Footnotes Common Stock, par value $0.001 per share 2020-07-02 4 S 0 35988 57.9756 D 10589044 I See Footnotes In addition to Vifor (International) Ltd., an entity formed under the laws of Switzerland ("Vifor"), and Vifor Fresenius Medical Care Renal Pharma Ltd., an entity formed under the laws of Switzerland ("VFMCRP"), this Form 4 is being filed by Vifor Pharma Ltd., an entity formed under the laws of Switzerland ("Vifor Pharma" and, together with Vifor and VFMCRP, the "Reporting Persons"). The business addresses for each of the Reporting Persons are listed above. Each of the Reporting Persons may be deemed to have a pecuniary interest in securities reported by it on this Form 4 (the "Subject Securities"). Beneficial ownership of the common stock referred to herein is being reported solely because (i) Vifor Pharma may be deemed to beneficially own 7,255,711 shares of Common Stock of ChemoCentryx, Inc. as a result of Vifor Pharma's indirect ownership of 100% of the equity interests of Vifor, and (ii) Vifor Pharma may be deemed to beneficially own 3,333,333 shares of Common Stock of ChemoCentryx, Inc. as a result of Vifor Pharma's indirect ownership of 55% of the equity interests of VFMCRP. Each of the Reporting Persons disclaims any beneficial ownership of any of the Subject Securities, except to the extent of any pecuniary interest therein. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Vifor on June 26, 2020. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.86 to $56.85, inclusive. Vifor undertakes to provide ChemoCentryx, Inc., any security holder of ChemoCentryx, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (5), (6) and (7) to this Form 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.88 to $57.87, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.88 to $58.21, inclusive. VIFOR (INTERNATIONAL) LTD, By: /s/ Oliver Kronenberg, Title: Group General Counsel, /s/ Markus Frenzen, Title: Group Treasurer 2020-07-07 VIFOR PHARMA LTD, By: /s/ Oliver Kronenberg, Title: Group General Counsel, /s/ Markus Frenzen, Title: Group Treasurer 2020-07-07 VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA LTD, By: /s/ Oliver Kronenberg, Title: Group General Counsel, /s/ Markus Frenzen, Title: Group Treasurer 2020-07-07